ESSA Pharma Inc.

Equities

EPIX

CA29668H7085

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-24 pm EDT			5-day change	1st Jan Change
6.25 ^USD	-2.34%		-11.60%	-5.30%

Mar. 06	Transcript : ESSA Pharma Inc. - Shareholder/Analyst Call
Mar. 06	Norway's wealth fund pushes for more women on emerging market company boards	RE

ESSA Pharma in Clinical Collaboration Agreement With Bayer

April 28, 2021 at 06:01 am EDT

By Michael Dabaie

ESSA Pharma Inc. said Wednesday it is in a clinical trial collaboration and supply agreement with Bayer.

ESSA, a clinical-stage pharmaceutical company, said the agreement is to evaluate its lead product candidate, EPI-7386, in combination with Bayer's darolutamide in patients with metastatic castration-resistant prostate cancer.

Under the agreement, Bayer may sponsor and conduct a Phase 1/2 study. ESSA said it will supply EPI-7386 for the trial and will retain all rights to EPI-7386. The clinical study is expected to start in 2021.

Write to Michael Dabaie at michael.dabaie@wsj.com

(END) Dow Jones Newswires

04-28-21 0801ET

Stocks mentioned in the article

	Add to a list Add to a list 0 selected To use this feature you must be a member Log in Sign up	Price	Change	5d. change	Capi.
	DOW JONES INDUSTRIAL	38,461 PTS	-0.11%	+1.75%	-
	BAYER AG	26.97 EUR	-1.37%	+2.74%	28.31B

Latest news about ESSA Pharma Inc.

Transcript : ESSA Pharma Inc. - Shareholder/Analyst Call	Mar. 06
Norway's wealth fund pushes for more women on emerging market company boards	Mar. 06	RE
ESSA Pharma Inc. Reports Earnings Results for the First Quarter Ended December 31, 2023	Feb. 13	CI
ESSA Pharma Inc. Reports Earnings Results for the Fourth Quarter Ended September 30, 2023	Dec. 12	CI
Essa Pharma Insider Bought Shares Worth $133,274, According to a Recent SEC Filing	Nov. 24	MT
Essa Pharma Insider Bought Shares Worth $419,661, According to a Recent SEC Filing	Nov. 16	MT
ESSA Pharma Inc. Presents Updated Phase 1 Masofaniten (EPI-7386) Clinical Data at the 30th Annual Prostate Cancer Foundation Scientific Retreat	23-10-26	CI
ESSA Pharma Files $200 Million Mixed Shelf	23-09-20	MT
ESSA Pharma Inc. Announces Initiation of Phase 2 Study Evaluating Masofaniten (EPI-7386) in Combination with Enzalutamide in Patients with Metastatic Castration-Resistant Prostate Cancer	23-09-18	CI
ESSA Pharma Inc.(NasdaqCM:EPIX) dropped from S&P Global BMI Index	23-09-18	CI
ESSA Pharma Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended June 30, 2023	23-08-08	CI
Essa Pharma Inc. Appoints Lauren Merendino to Its Board of Directors	23-06-06	CI
ESSA Pharma Inc. Reports Earnings Results for the Second Quarter and Six Months Ended March 31, 2023	23-05-09	CI
ESSA Pharma Signs Clinical Trial Support Deal With Janssen to Evaluate EPI-7386 Combinations to Treat Prostate Cancer	23-04-12	MT
ESSA Pharma Inc. Announces Clinical Trial Support Agreement with Janssen Research & Development, LLC	23-04-12	CI
ESSA Pharma Inc. Reports Earnings Results for the First Quarter Ended December 31, 2022	23-02-07	CI
Transcript : ESSA Pharma Inc. Presents at B. Riley Securities' 3rd Annual Oncology Conference, Jan-19-2023 11:00 AM	23-01-19
Oppenheimer Adjusts ESSA Pharma's Price Target to $17 From $23, Maintains Outperform Rating	22-12-14	MT
Earnings Flash (EPIX) ESSA PHARMA Posts Q4 Loss $-0.14	22-12-13	MT
ESSA Pharma Inc. Reports Earnings Results for the Fourth Quarter Ended September 30, 2022	22-12-13	CI
ESSA Pharma Inc. Reports Earnings Results for the Full Year Ended September 30, 2022	22-12-13	CI
ESSA Pharma, Janssen Suspend Enrollment in Prostate Cancer Treatment Study; ESSA Pharma Shares Sink	22-10-31	MT
Essa Pharma Shares Drop 26% After Janssen Suspends Enrollment for Trials	22-10-31	DJ
ESSA Pharma Inc. Provides an Update on Its Clinical Collaboration with Janssen	22-10-31	CI
Health Care Up After Bristol Myers Earnings -- Health Care Roundup	22-10-26	DJ

Chart ESSA Pharma Inc.

Duration

Period

More charts

Company Profile

ESSA Pharma Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is focused on developing proprietary therapies for the treatment of patients with prostate cancer. Its lead candidate, EPI-7386, is an oral, small molecule that inhibits the N-terminal domain of the androgen receptor (AR). The Company is completing the initial Phase I clinical development of EPI-7386 as a monotherapy treatment for patients with metastatic castration-resistant prostate cancer (mCRPC). The Company is also developing ANITen bAsed Chimera (ANITAC) AR NTD degraders to suppress androgen biology.

Sector

Biotechnology & Medical Research

Calendar

2024-05-06 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

8.576 CAD

Average target price

27.08 CAD

Spread / Average Target

+215.73%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
ESSA PHARMA INC.	-5.30%	276M
IQVIA HOLDINGS INC.	+4.09%	43.84B
LONZA GROUP AG	+47.81%	41.25B
MODERNA, INC.	+9.45%	41.68B
CELLTRION, INC.	-10.92%	27.04B
ICON PUBLIC LIMITED COMPANY	+9.32%	25.53B
ALNYLAM PHARMACEUTICALS, INC.	-24.87%	18.18B
MEDPACE HOLDINGS, INC.	+29.70%	12.29B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	+1.28%	12.29B
UNITED THERAPEUTICS CORPORATION	+7.78%	11.15B

Other Biotechnology & Medical Research